# Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

> **NCT03125928** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT03125928
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-13
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03125928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03125928, "Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03125928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*